SWOG S1216 A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Objective

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.

https://www.clinicaltrials.gov/ct2/show/NCT01809691

Location:

Essentia Health Duluth

Disclosures:

None

For more information about a financial conflict of interest (FCOI) or to review the Essentia Health FCOI policy, click here.

Last Updated: 05/11/2015

Research Study Categories

  • Adult Studies

Specialty

  • Cancer
  • Genitourinary Cancer
Contact
Cancer Clinical Trials at 218-786-3308